Conservative as it should be for a 12 month target.
Long term one needs to calculate the value of 15%+ royalties earned in a $3+B market without a viable competing drug for 10 years.
i.e. $450,000+ per annum.
Hell, be conservative and assume all the milestone payments only cover off all of the costs of commercialization and ongoing ops.
$4.5B plus in royalties.
Big numbers.
$2, page-27
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 46.5¢ | 44.0¢ | $1.428M | 3.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109582 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 21213 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |